Background
==========

As single agents, durvalumab (MEDI4736), a human IgG1 anti-PD-L1 antibody, and tremelimumab, a human IgG2 anti-CTLA-4 antibody, have shown acceptable safety profiles and antitumor activity. Similar to other anti-PD-L1/anti-PD-1 monotherapies, durvalumab has shown greater objective tumor response rates in PD-L1-positive patients compared with PD-L1-negative patients. Anti-CTLA4 therapies activate T-cells and may increase immune infiltrate and PD-L1 expression in tumor cells and tumor infiltrating immune cells. Thus, combination therapy with durvalumab and tremelimumab could be active in NSCLC regardless of baseline PD-L1 expression.

Methods
=======

This is a phase 1, open-label, dose-escalation/expansion study (NCT02000947) of D+T in patients with Stage III/IV NSCLC (any number of prior lines of therapy; immunotherapy-naïve). The primary endpoint is safety and tolerability; secondary endpoints include investigator-reported RECIST v1.1 response. PD-L1 expression was tested retrospectively using an immunohistochemical assay (Ventana).

Results
=======

As of 1 June 2015, 102 patients received treatment in the dose escalation phase; combinations of durvalumab \[3 mg/kg (D3) to 20 mg/kg (D20) every 2 (q2w) or 4 weeks (q4w)\] and tremelimumab \[1 mg/kg (T1) to 3 mg/kg (T3)\] q4w, plus a D15 + T10 combination, were explored. Across all cohorts, 80% and 42% of patients had ≥1 treatment-related AE (any Grade and Grade 3/4, respectively); 28% discontinued treatment due to a related AE. A greater frequency of AEs, without a corresponding increase in tumor response, was seen with increasing T dose. In the combined T1 cohort (D10--D20), 73% and 30% of patients had ≥1 related AE (any Grade and Grade 3/4, respectively); 16% discontinued treatment due to a related AE. There were 3 treatment-related deaths (myasthenia gravis, T1; pericardial effusion, T1; neuromuscular disorder, T3).

84 patients (73 EGFR/ALK wild-type; 77 non-squamous; 48 with ≥2 prior lines of therapy) were evaluable for response (Table [1](#T1){ref-type="table"}). The overall response rate (confirmed+unconfirmed) was 25%. Higher response rates were observed in those with 1 vs ≥2 prior therapies. Response rates do not appear dependent on PD-L1 status: 35% (PD-L1-positive), 22% (PD-L1-negative, \<25% tumor cell staining) and 33% (PD-L1-negative, 0% tumor cell staining). Similar findings were observed for the combined T1 cohort. D+T also showed good durability of response similar to that seen for monotherapy.

###### 

Response rates (Confirmed/unconfirmed with ≥16 weeks follow-up)

                     Overall population   EGFR/ALK wild-type population                                                                                                          
  ------------------ -------------------- ------------------------------------------ ------------- ------------------------------------------ ------------ -------- ------------ ---------
                     All cohorts          Combined cohort: D10--20 q4w or q2w + T1   All cohorts   Combined cohort: D10--20 q4w or q2w + T1                                      
                                                                                                                                                                                 
                     n/N (%)              95% CI                                     n/N (%)       95% CI                                     n/N (%)      95% CI   n/N (%)      95% CI
                                                                                                                                                                                 
  All patients       21/84 (25)           16--36                                     11/39 (28)    15--45                                     21/73 (29)   19--41   11/34 (32)   17--51
  PD-L1^+^ (≥25%)    7/20 (35)            15--59                                     3/9 (33)      8--70                                      7/17 (41)    18--67   3/9 (33)     8--70
  PD-L1^-^ (\<25%)   11/49 (22)           12--37                                     6/23 (26)     10--48                                     11/45 (24)   13--40   6/19 (32)    13--57
  PD-L1^-^ (0%)      9/27 (33)            17--54                                     6/12 (50)     21--79                                     9/26 (35)    17--56   6/11 (55)    23--83
  All 2L patients    15/32 (47)           29--65                                     7/16 (44)     20--70                                     15/31 (48)   30--67   7/15 (47)    21--73
  PD-L1^+^ (≥25%)    6/8 (75)             35--97                                     2/3 (67)      9--99                                      6/8 (75)     35--97   2/3 (67)     9--99
  PD-L1^-^ (\<25%)   7/18 (39)            17--64                                     4/11 (36)     11--69                                     7/17 (41)    18--67   4/10 (40)    12--74
  PD-L1^-^ (0%)      6/8 (75)             35--97                                     4/5 (80)      28--100                                    6/8 (75)     35--97   4/5 (80)     28--100

2L, second line: 1 prior line of therapy, receiving D+T in second line

Conclusions
===========

D+T at selected phase 3 dose (D20, T1) has a manageable tolerability profile and anti-tumor activity in NSCLC. Unlike anti- PD-1/PD-L1 monotherapies, the combination of D+T appears to be active regardless of PD-L1 status, including even in patients with no tumor cell membrane PD-L1 staining, a setting where patients would not be expected to derive significant benefit from anti-PD-1/PD-L1 monotherapy over current standard of care \[[@B1],[@B2]\].
